9 year track record of working with the largest players in the cannabis and vaping industries
April 23, 2020
4 min to read

Will Nicotine Be a Game Changer for COVID-19 Patients?

Vaping360 placeholder image
Jim McDonald

Does nicotine protect users from contracting the coronavirus SARS-CoV-2, or reduce its impact once it’s in the body? These are serious questions—and highly controversial ones—and we may have solid answers soon.

A clinical trial is set to begin in France, providing nicotine patches to hospital staff and COVID-19 patients and measuring the results. The trial has the backing of celebrated Pasteur Institute neurobiologist Jean-Pierre Changeux, an expert on the cholinergic system (which includes the nicotinic receptors).

Because most COVID-19 patient data has measured the number of infected smokers, but has not identified smokeless tobacco or e-cigarette users, it’s possible that some other component in tobacco smoke is exerting a protective effect. But the interaction between nicotine and the receptors used for access to the organs by the coronavirus is the only hypothesis that has so far been advanced by researchers, and it seems the most probable.

Scientists have speculated about the potential protective effects of nicotine since the earliest coronavirus data from China showed that smokers were infected at far lower rates than the general public. We noted in a March 12 story that five studies from China showed that just 3.9-14.5 percent of diagnosed COVID-19 patients were listed as smokers, while the smoking rate for Chinese men is about 50 percent. That gulf has been seen again and again as data came in from other cohorts.

In late January, New Zealand pharmaceutical researcher and harm reduction advocate Eliana Golberstein Rubashkyn posed a possible mechanism by which nicotine could prevent the coronavirus from adhering to the receptors in the body’s cells that are its prime entry point. She posted her suggestion on Twitter.

In late March, cardiologist and e-cigarette researcher Konstantinos Farsalinos published a preliminary study that noted the low number of smokers in published data, and proposed a similar explanation. Nicotine might block the coronavirus from finding its target cells, Farsalinos said.

Since then, data from other countries—including the United States and France—have shown similar low rates of infection among smokers, and Farsalinos has updated his study with the new information. His hypothesis has evolved to also suggest that nicotine might modulate the “hyperinflammatory” reaction of the immune system (the so-called cytokine storm) that has been noted in some of the worst COVID-19 cases. If that's correct, nicotine might help prevent infection, and also reduce the damage caused in already infected patients.

Farsalinos calls for clinical trials with nicotine replacement therapies to test his hypothesis. The final journal publication of his paper—co-written with his University of West Attica (Greece) colleague Prof. Anastasia Barbouni and New York University Prof. Raymond Niaura—is due soon.


But Dr. Changeux and his French colleagues may have beaten the Farsalinos team to the punch—at least for purposes of fame and glory. Their paper, which wasn’t published in preliminary form until nearly a month after Farsalinos’ early version appeared, follows almost exactly the same methodology (applied to a group of French patients) and has essentially the same conclusions as the Farsalinos paper. Yet they don’t cite Farsalinos’ work.

Controversies in science are nothing new. Even theft of theories and outright plagiarism are not unheard of. But it would be a shame if Dr. Farsalinos, who has devoted so much of his life to research on nicotine and vaping, doesn’t get part of the public acclaim if nicotine indeed prevents deaths from COVID-19.

Whoever gets credit for the discovery may have to move mountains to convert the knowledge into widespread action. Tobacco control and public health interests will be lined up against any conclusion that nicotine could be beneficial to society as a whole. Anyone advocating preventive use of nicotine products—even those proven to be non-addictive, like patches—will be skewered and roasted alive by the industry that has spent the last 30 years turning the public perception of nicotine into something resembling a demonic plague.

Vaping360 placeholder image

Jim McDonald

Vaping since: 13 years

Favorite products:

Favorite flavors: RY4-style tobaccos, fruits

Expertise in: Political and legal challenges, tobacco control haters, moral panics

Jim McDonald

Smokers created vaping without help from the tobacco industry or anti-smoking crusaders, and I believe vapers have the right to continue innovating to help themselves. My goal is to provide clear, honest information about the challenges vaping faces from lawmakers, regulators, and brokers of disinformation. I’m a member of the CASAA board, but my opinions aren’t necessarily CASAA’s, and vice versa. You can find me on Twitter @whycherrywhy

Related Articles



Join the discussion

There are no comments yet.
Be the first one to add a comment.

Vaping360® is the world’s largest vaping media website with over 1 million monthly visitors.

footer illustration
© Vaping360, All Rights Reserved.